개서양대황

Herbal Teas and Thrombocytopenia: A Curious Case of Yellow Dock and Burdock-Induced Thrombocytopenia.

1. Eur J Case Rep Intern Med. 2022 Mar 25;9(3):003247. doi: 10.12890/2022_003247. eCollection 2022. Herbal Teas and Thrombocytopenia: A Curious Case of Yellow Dock and Burdock-Induced Thrombocytopenia. Latif A(1), Fichadiya H(1), Abid F(1), Capo G(2). Author information: (1)Department of Intern

Prevalence of positive reactions in intradermal and IgE serological allergy tests in dogs from South Australia, and the subsequent outcome of allergen-specific immunotherapy.

2. Aust Vet J. 2020 Jan;98(1-2):17-25. doi: 10.1111/avj.12892. Epub 2019 Nov 19. Prevalence of positive reactions in intradermal and IgE serological allergy tests in dogs from South Australia, and the subsequent outcome of allergen-specific immunotherapy. Han C(1), Chan WY(1), Hill PB(1). Autho

Antioxidant activity of yellow dock (Rumex crispus L., Polygonaceae) fruit extract.

3. Phytother Res. 2011 Jan;25(1):101-5. doi: 10.1002/ptr.3234. Antioxidant activity of yellow dock (Rumex crispus L., Polygonaceae) fruit extract. Maksimović Z(1), Kovacević N, Lakusić B, Cebović T. Author information: (1)Institute of Pharmacognosy, School of Pharmacy, University of Belgrade, B

Effects of Rumex nervosus leaf powder supplementation on carcasses compositions, small intestine dimensions, breasts color quality, economic feasibility in broiler chickens.

1. Poult Sci. 2023 Oct;102(10):102943. doi: 10.1016/j.psj.2023.102943. Epub 2023 Jul 18. Effects of Rumex nervosus leaf powder supplementation on carcasses compositions, small intestine dimensions, breasts color quality, economic feasibility in broiler chickens. Qaid MM(1), Al-Mufarrej SI(2), Al-Garadi MA(2), Al-Haidary AA(2). Author information: (1)Department of Animal Production, College of Food and Agriculture Sciences, King Saud University, Riyadh, 11451, Saudi Arabia. Electronic address: mqaid@ksu.edu.sa. (2)Department of Animal Production, College of Food and Agriculture Sciences, King Saud University, Riyadh, 11451, Saudi Arabia. Carcass characteristics, product quality, and the conversion of feed into meat with higher performance and feasibility are important determinants of the profitability and sustainability of any poultry enterprise. The objective of this study was to investigate the potential effect of Rumex nervosus leaf powder (RNLP) on carcass composition, small intestine dimensions, breast color quality, and economic feasibility of Ross broiler chickens. A total of 122 broilers were randomly distributed evenly among 4 treatments (0, 1, 3, and 5 g RNLP/ kg diet, n = 5 replicates per treatment, with 6 broilers per replicate: 3 ♀ and 3 ♂). Performance and economic data were collected in each replicate during the experiment. One male bird from each replication was examined for other criteria on d 34. Results showed that broilers fed 3 g of RNLP had a higher eviscerated carcass weight and dressing percentage (P < 0.05) than the control. The RNLP-fed broilers had higher weights and thicknesses in the duodenum and jejunum of up to 5 g and in the ileum and overall small intestine of up to 3 g. Broilers fed the lowest levels of RNLP had the highest revenue and net gain and the lowest cost-benefit ratio compared with those fed the highest levels of RNLP. The results indicate that the addition of RNLP has a positive effect on carcass processing, the intestinal measurements, and profitability ratios of the broilers. The 1 g RNLP/kg feed is the recommended dose to increase productivity and economic profitability ratios per kilogram of meat. Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. DOI: 10.1016/j.psj.2023.102943 PMCID: PMC10403739 PMID: 37523995 [Indexed for MEDLINE]

Microbiological and Clinical Effects of a Proanthocyanidin-enriched Extract from Rumex acetosa in Periodontally Healthy Carriers of Porphyromonas gingivalis: a Randomized Controlled Pilot Study.

2. Planta Med. 2023 Sep;89(11):1052-1062. doi: 10.1055/a-1728-2249. Epub 2021 Dec 25. Microbiological and Clinical Effects of a Proanthocyanidin-enriched Extract from Rumex acetosa in Periodontally Healthy Carriers of Porphyromonas gingivalis: a Randomized Controlled Pilot Study. Selbach S(1), Klocke A(2), Peters U(3), Beckert S(4), Watt RM(5), Tong R(5), Flemmig TF(5), Hensel A(4), Beikler T(3). Author information: (1)Adelaide Dental School, The University of Adelaide, Adelaide, Australia. (2)Private Practice, Krefeld, Germany. (3)Department of Periodontics, Preventive and Restorative Dentistry, University Medical Center Eppendorf, Hamburg, Germany. (4)Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Münster, Germany. (5)Faculty of Dentistry, The University of Hong Kong, Hong Kong SAR, Peoples' Republic of China. Rumex acetosa significantly inhibits the adhesion of Porphyromonas gingivalis (P. g.) to eukaryotic host cells in vitro. The objective of this randomized placebo-controlled pilot-trial was to analyze effects of a mouth rinse containing 0.8% (w/w) of a quantified proanthocyanidin-enriched extract from Rumex acetosa (RA1) on microbiological, clinical, and cytological parameters in systemically healthy individuals without history of periodontitis, harboring P. g. intraorally. 35 subjects received a supragingival debridement (SD) followed by mouth rinsing (3 times daily) with either RA1 mouth rinse solution (test) or placebo (control) for 7 days as adjunct to routine oral hygiene. Supragingival biofilm samples were taken at screening visit, baseline (BL), 2, 4, 7 and 14 days after SD. P. g. and 11 other oral microorganisms were detected and quantified by rtPCR. Changes in the oral microbiota composition of one test and one control subject were assessed via high throughput 16S rRNS gene amplicon sequencing. Approximal Plaque Index (API) and the modified Sulcular Bleeding Index (SBI) were assessed at BL, 7- and 14-days following SD. Brush biopsies were taken at BL and 14 d following SD. Intergroup comparisons revealed no significant microbiological, cytological, and clinical differences at any timepoint. However, a significant reduction in SBI at day 14 (p = 0.003) and API at day 7 (p = 0.02) and day 14 (p = 0.009) was found in the test group by intragroup comparison. No severe adverse events were observed. The results indicate that RA1 mouth rinse is safe but does not seem to inhibit colonization of P. g. or improve periodontal health following SD. Thieme. All rights reserved. DOI: 10.1055/a-1728-2249 PMID: 34953469 [Indexed for MEDLINE] Conflict of interest statement: The authors T. B. and A. H. filed a patent application “Use of proanthocyanidins for production of an antiadhesive preparation”, priority DE/14.09.09/DEA102009027696, on the 14.09.2009. However, the authors state that this application had no impact on the study protocol, its execution and evaluation and TB and AH refrained from data collection and data analysis.

Topical Treatments for Melasma: A Systematic Review of Randomized Controlled Trials.

3. J Drugs Dermatol. 2019 Nov 1;18(11):S1545961619P1156X. Topical Treatments for Melasma: A Systematic Review of Randomized Controlled Trials. Austin E, Nguyen JK, Jagdeo J. Background: Melasma is an acquired skin disease characterized by symmetric hyperpigmentation on sun-exposed areas, particularly on the face. Recently, there has been tremendous scientific interest in novel, safe, and effective topical agents to manage melasma. Objective: To evaluate topical treatments for melasma and provide evidence-based recommendations for clinical use and further research. Methods: We performed a systematic review of randomized controlled trials (RCTs) on topical agents for the treatment of melasma on March 4th, 2019 using PRISMA guidelines. Clinical recommendations were based on the American College of Physicians guidelines. Results: After screening, we identified 35 original RCTs using azelaic acid, cysteamine, epidermal growth factor, hydroquinone (liposomal-delivered), lignin peroxidase, mulberry extract, niacinamide, Rumex occidentalis, triple combination therapy, tranexamic acid, 4-n-butylresorcinol, glycolic acid, kojic acid, aloe vera, ascorbic acid, dioic acid, ellagic acid and arbutin, flutamide, parsley, or zinc sulfate for melasma. Conclusions: Cysteamine, triple combination therapy, and tranexamic acid received strong clinical recommendations for the treatment of melasma. Cysteamine has excellent efficacy and is reported to have anti-cancer properties, but has not been directly compared with hydroquinone. Triple combination agents and tranexamic acid are effective, but carry theoretical risks for ochronosis and thrombosis, respectively. Natural compounds are associated with low risk for adverse events, but more research is needed to determine the efficacy, optimal formulation, and appropriate concentration of novel treatments. J Drugs Dermatol. 2019;18(11):1156-1171. PMID: 31741361 [Indexed for MEDLINE]

Natural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17.

4. Ophthalmology. 2019 Feb;126(2):261-273. doi: 10.1016/j.ophtha.2018.08.017. Epub 2018 Aug 22. Natural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17. Yu JJ(1), Agrón E(1), Clemons TE(2), Domalpally A(3), van Asten F(4), Keenan TD(1), Cukras C(1), Chew EY(5); Age-Related Eye Disease Study 2 Research Group. Collaborators: Chew EY, Ferris FL 3rd, SanGiovanni JP, Agrón E, Clemons T, Lindblad A, Lindblad R, Shah N, Sperduto R, McBee W, Gensler G, Harrington M, Henning A, Jones K, Thotapally K, Tull D, Watson V, Williams K, Gentry C, Kaufman F, Morrison C, Saverino E, Schenning S, Blodi B, Danis RP, Davis M, Domalpally A, Glander K, Guilfoil G, Hubbard LD, Johnson K, Klein R, Nardi B, Neider M, Robinson N, Rosensteel E, Wabers H, Zhang G, Ruby AJ, Capone A Jr, Dass B, Drenser K, Garretson BR, Hassan TS, Trese M, Williams GA, Wolfe J, Bell T, Zajechowski M, Bezaire D, McIver F, Medina A, Pagett J, Smith SH, Swartz L, Treuter T, Antoszyk A, Brown J, Browning DJ, Holland W, Karow A, Stalford K, Price A, Ennis S, Fredenberg S, Herby J, Balasubramaniam U, Clark L, McClain D, McOwen M, Watson L, Klein M, Bailey ST, Hwang TJ, Lauer A, Stout JT, McCollum P, Johnson M, Rice PB, Kim I, Loewenstein J, Miller J, Sobrin L, Young L, Sullivan J, Houlihan P, Merry L, Lane AM, Bator UL, Evans C, Brett S, Callahan C, Grillo M, Walsh D, Zimmerman KL, Fish GE, Anand R, Coors LE, Fuller DG, Spencer R, Wang RC, Duignan K, Arceneaux S, Aguado H, Hesse N, Mackens M, Swan B, Wong WT, Cukras C, Dalal M, Jacobs-El N, Meyerle C, Nicholson B, Wiley H, Shimel KH, Garced A, Oparah J, Short G, Temple A, Ayukawa B, Foster G, Hayes D, Koutsandreas D, Nashwinter R, Rowan J, Chew EY, Bono M, Cunningham D, Palmer M, Zetina A, Orth DH, Rezaei K, Civantos J, Hasan S, Packo K, Figliulo C, Stanberry P, Farmer T, Nelson K, Townsend-Patrick S, Rosenfeld P, Chen R, Doshi R, Dubovy S, Kim BT, Lowrance M, Moshfeghi A, Nahas Z, Schienbaum G, Vishak J, Weng C, Yehoshua Z, Rodriguez B, Rebimbas J, Gleichauf J, Kicak M, Mena J, Odem T, Sferza-Camp E, Disgdiertt A, Oramas J, Rams I, Thatcher S, Bressler SB, Bressler NM, Finkelstein D, Sherman SH, Solomon S, Ying HS, Denbow R, Phillips D, Radcliffe E, Belt J, Cain D, Emmert D, Herring M, McDonald J, Hubbard GB, Bergstrom CS, Cribbs B, Hendrick A, Johnson B, Laird P, Mehta S, Olsen T, Townsend J, Yan J, Yeh S, Curtis L, Brower J, Yi H, Dobbs JR, Jordan D, Elman MJ, Liss RA, Starr J, Belz J, Putzulo C, Coffey T, Davis A, Singletary P, Andreani GS, Cain T, Ketner D, Sotirakos P, Chandra S, Blodi BA, Altaweel MM, Danis RP, Gottlieb JL, Ip M, Klein R, Nork TM, Stevens TS, Burke K, Olson S, Dietzman K, Soderling B, Somers G, Wealti A, Krolnik D, Peterson J, Reed S, Friberg T, Eller A, Gallagher D, Labriola L, Pokrifka M, Gedansky A, Anthony N, Grzybowski C, Matthews D, Murajda-Jumba S, Toro J, Fish GE, Callanan DG, Solley WA, Williams P, Lash S, Boleman B, Dock C, Fish GE, Shami M, Arrington B, Meeks A, Ruby AJ, Margherio AR, Raphaelian P, Markus D, Langdon J, Truax E, Lewis S, Terry B, Ruby AJ, Noffke A, Oh K, Sarrafizadeh R, Sneed S, Hammersley J, Neal S, Doran M, Jones N, Preston L, Jessick H, Marsh TT, Tolentino M, Berger A, Hamilton R, Misch D, Moon SJ, Sutherland D, Dilts V, Henderson S, Medina E, Trueman D, Holm L, Strickland J, Ie D, Lipkowitz JL, Shah KB, Geraghty S, Sannazzaro B, Harper M, Bayer K, Lansing MB, Fox LB, Lee R, Stallman JB, Jacobson M, Koh S, Lampert S, Miller J, Rivellese M, Sharma A, Stoltz RA, Vanderveldt S, Marcus L, Hendricks S, Hollman R, Betanzos G, Ellorin L, Fulbright S, McCormick D, Edwards PA, Hall J, Monk M, Gutkowski M, Mazurek M, Murphy J, Gusas K, Moffett C, Burley D, Chesney N, Kilgo K, Rusinek B, Stern B, Troszak T, Baker-Levingston R, Baker CW, Caldwell T, Walker T, Lambert LF, Martin T, Palmer MJ, Williams T, Novak MA, Coney J, Miller DG, Pendergast S, Singerman L, Zakov N, Zegarra H, DuBois K, Rath S, Revella L, Brink T, Drury K, Hogue L, Ilc M, Keller C, McNamara E, Tanner V, Cunningham T, DuBois J, Greanoff G, Nitzsche T, Smith-Brewer S, Isernhagen RD, Kitchens JW, Stone TW, Wood WJ, Holcomb D, Therrien V, Buck M, Van Arsdall J, Slade E, Schneiderman TE, Spinak DJ, Gaedke J, Brown HD, Helgren D, Pangelinan JG, Halperin L, Anagnoste S, Dhalla M, Rosenberg K, Taney B, Thompson WS, Lopez J, Hamlin M, Lopez M, Mariano J, Quinchia E, Aramayo P, Veksler R, Lee M, Dreyer R, Handelman I, Ma C, Peters M, Hobbs S 3rd, Milliron A, Kopfer M, Connaughton M, Hoerner AC, Logan RJ, Wohlsein HJ, Boyer D, Chu TG, Dayani P, Liao D, Novack RL, Rahhal FM, Roe R, Tabandeh H, Bayramyan J, Gasparyan T, Hoang C, Kurokouchi J, Lo TE, Ngo R, Nguyen MA, Peyton M, Yoon C, Sierra J, Zamboni A, Kessinger J, Protacio E, Smucker A, Rath P, Bergren R, Doft B, Liu J, Olsen K, Merlotti L, Ingram W, Marfisi K, Yeckel K, Carmelo HS, Fec A, McBroom K, Steinberg D, Levy M, Abrams J, Chen M, Torres W, Jelemensky P, Prybylski M, Raphael T, Appleby D, Rodman C, Sneath M, Rosa RH Jr, Hoelscher V, Castano A, Parker J, Hoskins J, Anderson N, Googe J Jr, McMillan TA, Miller J Jr, Perkins S, Oliver K, Beerbower J, Gilliland B, Hunt C, Jacobus M, Lince R, Morris C, Oelrich S, Whetstone J, Chan CK, Lin S, Walther K, Gonzales T, Myers L, Huff K, Brown DM, Chen E, Benz MS, Fish RH, Kim RY, Major J Jr, Wong TP, Wycoff C, Cone C, Gilaspia DG, Landaverde N, Smith R, Zamora D, Sneed V, Vela M, Kegley E, Greven C, Kurup S, Richards C, Slusher M, Everhart C, Fish J, Clark M, Miller D, Tyler M, Jumper JM, Fu AD, Johnson RN, Lujan B, McDonald HR, Rodriguez R, Ansari N, Joaquin J, Linares S, Lopez L, Sabio J, Grout S, Indermill C, Urias Y, Zimmerman R, Margulies L, Schmidt SJ, Meier JL, Hadley SL, Rosenthal W, Johnson B, Swafford L, Shields R, Varner RS, Rosen R, Gentile R, Rivas M, Tai KW, Carrasquillo-Boyd W, Masini R, Stoller G, Carnevale K, LaRosa DM, Burger B, Conway T, Del Castillo C, Diaz J, Jones S, Mondoc N, Balfour C, Vitha CH, Lutz J, McGinley B, El Baba F, Lavorna AM, Jones R, Lewis J, Tenzler R, Salvas-Mladek M, Van Kesteren D, McLean WC Jr, Bridges WZ Jr, Stone C, Ammons D, Lamy M, Menzel A, Raymer LD, Campbell B, Hawkins L, Rickman L, Sherlin L, Price P, Sinyai A, Kingsley R, Bradford RH Jr, Leonard RE 2nd, Icks S, Bergman V, Ross B, Burris R, Butt A, Richmond R, Lyon A, Gill M, Jampol L, Mizra R, Rozenbajgier Z, Chapman J, Kaminski L, Degillio A, Simjanoski E, Heier J, Cho H, Cleary TS, Goldman D, Shah C, Topping T, Weber M, Wiegand T, Schindelheim J, Bankert J, Stone J, Nowak A, Chong S, Williams L, Bennett S, Donovan D, Graham M, Jones C, Fung A, Bayabo JK, Bosch R, Cruz E, Emerson A, Fleming A, Barsness D, Rodriguez J, Soboleva M, Scott IU, Bowie E, Neely KA, Quillen DA, Walter L, Bennett T, Strong J, Wells J 3rd, Clark L, Johnson D, Miller P, Taylor M, Swinford T, Spivey R, Banach M, Ho L, Lanning R, Pheasant TR, Prensky JG, Truong S, Teatsworth J, Dietrich M, Wasilus A, Miller A, Rakes M, Slagle T, Richards M, Schuessler P, Stover L, Beer P, Falk NS, Shannon MB, Olmeda J, Berdeen D, Fisher JF Jr, Folk J, Russell S, Taylor B, Hinz C, Walshire J, Stockman H, Critser B, Karakas S, Montague C, Verdick R, Gupta O, Maguire J, Brady C, DeCroos FC, Dollin M, Garg S, Gerstenblith A, Haller J, Ho AC, Hsu J, Kaiser R, Pitcher J, Regillo C, Shah R, Spirn M, Tasman W, Vander J, Senderowitsch N, Formoso M, Markun M, George C, Centinaro C, Grande L, Carey S, Liebenbaum E, Sadda S, Humayun M, Sierra R, Corona E, Padilla M, Nu M, Ramos S, Barnett C, Currie G, Gottlieb C, Garfinkel R, Berinstein D, Colyer M, Deegan W 3rd, Min-Shyue Lai M, Murphy R, Osman M, Rivers M, Sanders R, von Fricken MA, Oliver D, Kirshon J, Snowden TA, Blondo T, Cronise A, Denny V, Mendez K, Newgen J, Davis J, Flory M, Frantz R, Murphy B, Rauch S, Kim JE, Bachman J, Connor TB Jr, Han DP, Stepian K, Weinberg DV, Wirostko WJ, Packard K, Kaczanowski T, Williams V, Barwick V, Flanders J, Backes D, Beringer J, Keller K, Selchert K, Bernstein P, Teske M, Vitale A, Allman S, Carlstrom B, Wegner K, Haroldsen A, Harrison D, Fry C, Gilman J, Jenkins G, Morris P, Rauser M, Fan J, Suthar M, Santiago G, Halsey KR, Quesada C, Kiernan W, Knabb J, Lewis RA, Dorenbach C, Spencer S, Barnett D, Morales J, Fishburne BC, Gross JG, Magee MA, Flowers A, McDowell A, Price R, Huang S, Tang J, Wilker S, Hornsby C, Ferguson L, Krogstad K, Adamovsky R, Allchin P, Carlton K, Clow C, Sholtis K, Burke S, Harrod M, Hrvatin S, Pankhurst G, Sabates NR, Cassell M, Desai K, Poulose A, Sabates F, Chen Y, Gallimore G, Konior Y, Kim N, Uwaydat S, Troillett D, Aletter K, Frank RN, Abrams G, Puklin J, Tewari A, Milanovic C, Bailey M, Griffith D, McDonald D, Morehead K, Sadikovic Z, Schillace L, Silvis E, Joondeph B, Christmas N, Johnson D, Kimura A, Liu M, Petty S, Zilis J, Benitez J, Catlett CB, Fluegel E, Mowry S, Nguyen H, Reflow D, Houghton OM, Garg S, Landers MB, Meredith T, Barnhart S, Karmalkar M, Cantrell D, Esquejo-Leon RL, Manor L, Pope S, Stines D, Stokely A, Hainsworth D, Helming D, Eichelberger D, Leaton MP, Hamm C, Chaum E, Iannaccone A, Jennings B, Murray T, Mastellone J, Millay R, Kim B, Goddard T, Beaudette LJ, Changelian-Aitken N, Corrada F, Dubuque J, Iezzi R, Bakri SJ, Pulido JS, Vogen D, Nielsen R, Berg K, Burrington J, Howard S, Overend J, Krason Z, Lewison D, Link T, Blinder KJ, Engelbrecht NE, Grand MG, Joseph DP, Shah GK, Smith B, Thomas M, Weeks R, Boyd L, Gabel D, Adelman R, Huang J, Kempton J, Parnes A, Dupont J, Perotti E, Donaldson V, Fong K, Ossorio P, Agarwal A, Sternberg P, Owings S, Adkins T, Lok E, Munn G, Skellie B, Bhagat N, Roy MS, Zarbin M, Fay C, Lazar M, Malpica B, Mikheyav T, Ulanski L 2nd, Lim J, Niec M, Johnson T, Ovando Y, Carroll CN, Janowicz M, Schwartz S, Cupp D, Gorin M, Heilweil G, Hosseini H, Hubschman JP, Kreiger A, McCannel TY, Pan C, Sarraf D, Tsui I, Udoetek J, Voleti V, Hitchcock L, Ostrick R, Chun M, Kageyama J, Davila N, Lipka K, Shin C, Owsley C, Albert M Jr, Feist R, Mason J, Thomley M, Johnson A, Clark M, Emond T, Hamela J, Marsh A, Searcey K, Rookard K, He YG, Ufret-Vincenty RL, Molai M, Anderson W, Horna J, Letson A, Cebulla C, Chang S, Davidorf F, Salerno J, Sladoje L, Stetson C, Perry J, Savage S, Toth C, Jaffe G, Schuman S, Sarin N, Crowell J, Keaton T, Kelly M, Lutman B, Skelly M, Welch L, Morse L, Hunter A, Soon-Chun Park S, Wallace C, Dhillon E, Salvador M, Holderreed B, Chandra K, Kaur S, Redenbo E, Hom S, Cooney M, Barbazetto I, Klancnik JM Jr, Sorenson JA, Yannuzzi L, Scolaro M, Agresta E, Gonzalez N, Grover S, Chalam KV, Gupta S, Lyons C, Li W, Patel C, Carrion J, Ferreyra H, Rodriguez A, Molina I, Balea G, Emory P, Rico M, Siqueiros G, Brucker AJ, Dunaief J, Grunwald J, Kim B, Maguire AM, VanderBeek B, Drossner S, DuPont J, Salvo R, Berger J, Devine C, Nyberg B, Weeney L, DiLoreto D, Chung M, Davis V, MacDowell P, Gara GO, Castillo D, Czubinski A, Keim M, Hardy B, Hollar RG, Schueckler L, Lyon AT, Weinberg A, Shiloach M, Pelkofer N, Zhou Q, McPoland L, Apte R, Rao PK, Pistorius S, Kambarian J, Adcock E, Gould S, Quinn M, Curtis R, Frost A, Meyer C, Rathert G. Author information: (1)Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland. (2)The Emmes Corporation, Rockville, Maryland. (3)Fundus Photographic Reading Center, The University of Wisconsin, Madison, Wisconsin. (4)Neurobiology-Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland. (5)Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: echew@nei.nih.gov. PURPOSE: To investigate the natural history and genetic associations of drusenoid pigment epithelial detachment (DPED) associated with age-related macular degeneration (AMD). DESIGN: Retrospective analysis of a prospective cohort study. PARTICIPANTS: Of the 4203 Age-Related Eye Disease Study 2 (AREDS2) participants, 391 eyes (325 participants) had DPED without late AMD at the time of DPED detection. Genetic analyses included 120 white AREDS2 participants and 145 Age-Related Eye Disease Study (AREDS) participants with DPED. METHODS: Baseline and annual stereoscopic fundus photographs were graded centrally to detect DPED, a well-defined yellow elevated mound of confluent drusen ≥433 μm in diameter, and to evaluate progression rates to late AMD: geographic atrophy (GA) and neovascular (NV)-AMD. Five single nucleotide polymorphisms (CFH [rs10611670], C3 [rs2230199], CFI [rs10033900], C2/CFB [rs114254831], ARMS2 [rs10490924]) and genetic risk score (GRS) group were investigated for association with DPED development. Kaplan-Meier analyses and multivariable proportional hazard regressions were performed. MAIN OUTCOME MEASURES: Progression rates to late AMD and decrease of ≥3 lines in visual acuity (VA) from the time of DPED detection; association of rate of DPED development with genotype. RESULTS: Mean (standard deviation [SD]) follow-up time from DPED detection was 4.7 (0.9) years. DPED was associated with increased risk of progression to late AMD (hazard ratio [HR], 2.36; 95% confidence interval [CI], 1.98-2.82; P < 0.001); 67% of eyes progressed to late AMD 5 years after DPED detection. Drusenoid pigment epithelial detachment was associated with increased risk of ≥3 lines of VA loss (HR, 3.08; CI, 2.41-3.93; P < 0.001) with 46% of eyes experiencing vision loss at 5 years (with or without progression to late AMD). ARMS2 risk alleles (1 vs. 0: HR, 2.72, CI, 1.58-4.70; 2 vs. 0: HR, 3.16, CI, 1.60-6.21, P < 0.001) and increasing GRS group (4 vs. 1) (HR, 12.17, CI, 3.66-40.45, P < 0.001) were significantly associated with DPED development in AREDS. There were no significant genetic results in AREDS2. CONCLUSIONS: This study replicates the results of previous natural history studies of eyes with DPED including the high rates of progression to late AMD and vision loss (regardless of progression to late AMD). The genetic associations are consistent with genes associated with AMD progression. Published by Elsevier Inc. DOI: 10.1016/j.ophtha.2018.08.017 PMCID: PMC6348044 PMID: 30142373 [Indexed for MEDLINE] Conflict of interest statement: Conflicts of Interest: Jeannette Yu, Elvira Agrón, Amitha Domalpally, Traci Clemons, Freekje van Asten, Tiarnan Keenan, Catherine Cukras, Emily Chew: None.

A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos.

5. Int J Dermatol. 2014 Nov;53(11):1412-6. doi: 10.1111/ijd.12690. Epub 2014 Sep 30. A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos. Mendoza CG(1), Singzon IA, Handog EB. Author information: (1)Department of Dermatology, Research Institute for Tropical Medicine, Filinvest Corporate City, Muntinlupa, Philippines. BACKGROUND: Melasma is a commonly acquired hyperpigmentation symmetrically distributed on the face, neck, and arms. The skin-lightening properties of Rumex occidentalis make it a therapeutic alternative to the reference standard treatment of hydroquinone (HQ). OBJECTIVES: This study was conducted to evaluate the safety and efficacy of 3% R. occidentalis cream versus 4% HQ cream in the management of epidermal and mixed melasma. METHODS: This was a randomized, double-blind, placebo-controlled trial. Forty-five subjects with epidermal and mixed melasma were recruited to compare 3% R. occidentalis cream, 4% HQ cream, and placebo cream applied twice daily for eight weeks. Changes in pigmentation were measured every two weeks using the Melasma Area Severity Index (MASI) and a mexameter. Adverse events were noted on every visit. Patient and investigator global evaluations were performed at the end of the study. RESULTS: Overall mean MASI and mexameter readings in the three groups decreased from baseline to week 8. The greatest decline in score from weeks 2 to 6 was achieved by the HQ group, followed by the R. occidentalis group. By week 8, the R. occidentalis group showed a greater mean ± standard deviation decline in MASI and mexameter readings from baseline (MASI: 0.60 ± 0.86; mexameter: 50.56 ± 25.63) than the HQ group (MASI: 0.55 ± 0.62; mexameter: 45.89 ± 47.83). The efficacy of R. occidentalis cream and HQ cream were assessed as similarly favorable by both study subjects and investigators. CONCLUSIONS: Rumex occidentalis 3% cream is a safe and effective skin-lightening agent for melasma and is comparable in efficacy with 4% HQ cream. © 2014 The International Society of Dermatology. DOI: 10.1111/ijd.12690 PMID: 25265986 [Indexed for MEDLINE]

Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis.

6. Rhinology. 2012 Dec;50(4):417-26. doi: 10.4193/Rhino.12.015. Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis. Jund R(1), Mondigler M, Steindl H, Stammer H, Stierna P, Bachert C; ARhiSi II study group. Author information: (1)Puchheim, Germany. OBJECTIVE: A herbal drug combination (Dry Extract BNO 1016) has been assessed for efficacy and tolerability in patients with acute viral rhinosinusitis. METHODOLOGY: In this randomised, controlled trial patients with symptom duration of up to 3 days, mild to moderate facial pain and a Major Symptom Score (MSS) between 8 and 12 were treated for 15 days with BNO 1016 or placebo (coated tablets administered orally). Primary efficacy endpoint was mean MSS at end of treatment. Secondary outcome measures included treatment response and changes in paranasal sinuses assessed by ultrasonography. RESULTS: Treatment resulted in clinically relevant, significant differences in mean MSS for BNO 1016 versus placebo. BNO 1016 provided symptom relief two days earlier than placebo. The number needed to treat for healing is 8. BNO 1016 was superior regarding responder rates at Day 10 and Day 14 and percentage of patients without signs of acute viral rhinosinusitis assessed by ultrasonography at end of treatment. BNO 1016 was well tolerated; no serious adverse events were reported. CONCLUSION: The herbal dry extract BNO 1016 is efficacious and well tolerated in patients with acute viral rhinosinusitis. TRIAL REGISTRATION: ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT01146860; EudraCT: 2009-016682-28). DOI: 10.4193/Rhino.12.015 PMID: 23193534 [Indexed for MEDLINE]